Byondis B.V.: Preclinical Data on the Potential of Byondis A

Overexpressed in Solid TumorsADC Currently in a First-in-Human Study NIJMEGEN, Netherlands, April 12, 2023 /PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical

Related Keywords

Netherlands , United Kingdom , Italy , Nijmegen , Gelderland , Belgium , United States , Dutch , American , Prnewswire Byondis , Wim Dokter , Conjugation Technology , First In Human Study , Molecular Cancer Therapeutics , American Association , Cancer Research , Byondis Chief Scientific Officer Wim Dokter , Next Generation Antibody Drug , Proprietary Linker Drug , Site Specific Conjugation , Good Manufacturing Practice , Byondis , Reclinical , Data , Potential , Yon3521 , Published , Olecular , Dancer , Herapeutics ,